The patient engagement engine for pharma portfolios

Medisafe has pioneered an ecosystem of digital solutions aimed at addressing critical Pharma challenges. The Medisafe Digital Companion stands out as a comprehensive tool that provides personalized medication management, reminders, and educational content. Research indicates that Medisafe users exhibit improved medication adherence rates, with some studies showing an adherence rate increase of over 20%.

Breast cancer remains one of the most prevalent malignancies worldwide, with an estimated 287,850 new invasive cases and 43,250 breast cancer–related deaths projected in the United States in 2025 (American Cancer Society, 2025). Despite advances in targeted oral therapies for extended adjuvant treatment, real‐world studies find that up to 50% of patients discontinue or skip doses, undermining efficacy (Mayo Clinic, 2024).

Multiple Sclerosis (MS) represents a formidable challenge in healthcare, a chronic, often unpredictable disease of the central nervous system that impacts millions worldwide. Its complex nature demands not just cutting-edge therapies but also robust, sustained patient support to navigate the daily realities of living with the condition.

Managing diabetes presents significant challenges both for patients and pharmaceutical companies. Adherence to medication regimens, continuous monitoring, and lifestyle adaptations are critical but often overwhelming.

Medication non-adherence is a $300B issue that can impact the cost of prescription drugs, medical care, and lead to serious health risks. Unfortunately, without greater support, non-adherence can become commonplace especially among patients with chronic disease. But medication non-adherence is more than just skipping a dose or forgetting a refill.

Here’s what today’s pricing development means for pharma brand marketers, patient support teams, innovation leads, access executives, and procurement leadership—and how Medisafe is uniquely positioned to drive higher adherence, long-term engagement, and ultimately better outcomes for those embarking on complex treatment journeys.

For the 133 million Americans who live with a chronic condition, and the 81 million who have two or more conditions, managing medications is more than just taking a pill. It becomes a priority to maintaining good health and the ability to live an active and fulfilling life.

Leading pharmaceutical companies are now using AI to help healthcare providers simplify and streamline the patient experience for specialty medications, which can be difficult to access, adhere to, and afford.

Medisafe’s real-world data shows that more than half of patients taking the most-prescribed antiplatelet meds have missed 1 to 5+ consecutive doses, leaving some untreated and at a greater risk of thrombosis and other complications.

This article explores how Medisafe’s intelligent patient engagement platforms provide unparalleled value to pharmaceutical executives, from driving adherence to surfacing actionable insights, and how these offerings are setting new standards in digitally enabled patient care. Discover the technologies and trends poised to shape pharma’s next competitive advantage.

This app led to a significant improvement in medication adherence for participants. 93% of patients reported that the app’s medication reminders helped them take their medications on time, a crucial factor in managing chronic conditions like hypertension, diabetes, and heart disease.

71% of Medisafe users improved their adherence after adding a Medisafe Medfriend who is alerted each time a dose is missed.

Medisafe data shows that more than 25% of patients who take a leading asthma medication do so in the morning. Guidelines from the National Asthma Education and Prevention Program (NAEPP) state that this medication should only be taken at night for maximum efficacy.

Can digital health survive economic uncertainty? Explore how pharma’s investment in patient engagement and EHR connectivity is building a recession-proof future for healthcare.

Worldwide medication adherence rates for most neurology conditions average 78% on Medisafe

Pharma knows where their pills go, but not what happens next. Explore how digital platforms provide the real-world evidence needed to understand the patient journey beyond the prescription.

Access our free launch toolkit, which has the must-have answers and best practices for all eight stages of a successful digital launch.

Discover how new technologies are driving the growth of digital health companions, and how these tools are advancing pharma.

Download our latest research showing how supporting patient engagement is not only a growing strategic initiative for pharma companies but is proving to be an impactful value driver.

Results showed that existing patients who joined the Medisafe program saw a 7% increase in adherence pre- vs. post-Medisafe start compared to those not on Medisafe, who showed no statistically significant increase over the same time frame.

Read how Medisafe and Pleio joined forces to help engage patients in their treatment journey through the power of human+digital connection, using a compassionate approach for the digital age to drive better outcomes.

In just five months, Merck KGaA, Darmstadt, Germany increased adherence rates up to 20% by customizing digital medication programs.

The rising cost of insulin is receiving more attention in the media and medical literature with the American Diabetes Association calling for solutions to insulin affordability. Medisafe data, however, indicate that cost may not be the highest concern for many insulin patients.

Why gastroenterology patients say they miss doses, and factors affecting those decisions.

Learn more about why dermatology patients say they miss doses, and factors affecting these decisions.

Medisafe’s real-world data shows patients treated for depression with a newer antidepressant brand (Brand-SSRI) are experiencing dramatically different perceived results in the first two months of therapy compared to patients on other SSRIs.

New data reveals a 10% increase in prescription refills for hypertensive patients using Medisafe. Discover how the "on-app" MPR jumped 21.8% for patients previously struggling with adherence.

Medisafe and IQVIA study shows 70% of non-adherent patients became adherent after using the app. Learn how the Medisafe platform impacts refill rates and long-term therapy duration.

Can an app save lives? New clinical research shows Medisafe significantly improves medication adherence for CHD patients. See the data behind the 0.47 MMAS-8 boost.

Medisafe dramatically improved adherence for cohorts of users who historically struggled, because following an HIV regimen correctly is critical to helping people with the disease live full and long lives. The proportion of patients with MPR ≥ 0.80 increased from 82.3% pre-app to 88.6% on-app, a 7.7% relative increase

Medisafe is a leading cloud-based mHealth platform for medication management, helping users worldwide adhere to even the most complicated medication schedules.

Discover why patients skip doses, when patients are most likely to skip doses, and factors affecting these decisions.

Medication non-adherence causes 125,000 deaths annually in the US. Learn how Medisafe’s ISPOR-presented research proves mobile technology can scale to lower healthcare costs and improve chronic disease outcomes.

The study focused on three areas; innovation, evidence, and adoption. IQVIA found that there are over 200 health apps introduced every day. While the majority of apps are focused on general wellness, 40% focus on managing specific conditions and that number is growing.

Medication non-adherence costs $100B annually. Learn how researchers used a standardized six-drug test to separate high-quality adherence apps from the rest of the market.

These study results are consistent with Medisafe’s previously announced findings that its users are 86% adherent to their medication regimens, versus the WHO’s estimate of 50 percent for the nation as a whole.

Medisafe was the highest-scoring app of the 10 apps assessed using MARS and had the highest scores in engagement and aesthetics. It was found to be interesting, entertaining, highly interactive, and customizable. Medisafe was the only app rated as having some evidence supporting its effectiveness in nonrandomized studies.